Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;43(8):4753-4759.
doi: 10.1007/s10072-022-06093-w. Epub 2022 Apr 29.

Plasma arylsulfatase A levels are associated with cognitive function in Parkinson's disease

Mingjian Li  1   2 , Xiaoxue Shi  2   3 , Jianjun Ma  4   5   6 , Wenhua Sun  2   3 , Zhidong Wang  2   3 , Dongsheng Li  2 , Jinhua Zheng  2 , Zhenxiang Zhao  2 , Qi Gu  2 , Siyuan Chen  2
Affiliations

Plasma arylsulfatase A levels are associated with cognitive function in Parkinson's disease

Mingjian Li et al. Neurol Sci. 2022 Aug.

Abstract

Background: Arylsulfatase A (ARSA), a lysosomal enzyme, has been shown to inhibit the aggregation and propagation of α-synuclein (α-syn) through its molecular chaperone function. The relationship between ARSA levels and Parkinson's disease (PD) in the Chinese Han population remains controversial, and few quantitative research studies have investigated the relationship between plasma ARSA levels and PD.

Objectives: The purpose of this study was to investigate the relationships between ARSA levels and cognitive function in PD patients and to evaluate the association of ARSA and α-syn levels with nonmotor symptoms.

Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma ARSA and α-syn levels in 50 healthy controls, 120 PD patients (61 PD patients with no cognitive impairment (PD-NCI) and 59 PD patients with cognitive impairment (PD-CI)). Motor symptoms and nonmotor symptoms (cognitive function, Unified Parkinson's Disease Rating Scale (UPDRS) score, depression, anxiety, constipation, olfactory dysfunction, sleep disruption, and other symptoms) were assessed with the relevant scales. The Kruskal-Wallis H test was used for comparison between groups, and Pearson/Spearman analysis was used for correlation analysis.

Results: The plasma ARSA concentrations were lower in the PD-CI group than in the PD-NCI group. The plasma α-syn levels in the PD-CI group were higher than those in the healthy control group, and the plasma ARSA levels were correlated with the Mini-Mental State Examination (MMSE scores) and Hoehn and Yahr (H-Y) stage.

Conclusion: We used a quantitative assessment method to show that low plasma ARSA levels and high α-syn levels are related to cognitive impairment in PD patients. Plasma ARSA levels gradually decrease with PD progression.

Keywords: Arylsulfatase A; Cognitive function; Parkinson’s disease; α-Synuclein.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A The plasma α-syn level in the PD-CI group was higher than that in the control group (P = 0.04). B The plasma ARSA level in the PD-NCI group was higher than that in the PD-CI group (P = 0.021). C Among the H-Y stages, 0 represents the control group. The plasma ARSA level of PD patients was higher than that of healthy controls, and with the progression of the disease, the plasma ARSA level exhibited a gradual significant decrease (P = 0.07)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim D, Jung BC, et al. Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an α-synuclein chaperone. Brain. 2019;142(9):2845–2859. doi: 10.1093/brain/awz205. - DOI - PubMed
    1. Song SK, Lee JE, Park H, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson’s disease according to cognitive status. Movement Disord. 2011;26(2):289–296. doi: 10.1002/mds.23477. - DOI - PubMed
    1. Yoo HS, Lee JS, Chung SJ, Ye BS, Sohn YH, Lee S, Lee PH (2020) Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease. Sci Rep-Uk 10(1):5567. 10.1038/s41598-020-62536-4 - PMC - PubMed
    1. Pan HX, Wang YG, Zhao YW, Zeng Q, Wang Z, Fang ZH, Zhang Y, Zhou X et al (2022) Evaluating the role of ARSA in Chinese patients with Parkinson’s disease. Neurobiol Aging 109:269–272. 10.1016/j.neurobiolaging.2021.08.008 - PubMed
    1. Ruan Y, Zheng R, Lin Z, Gao T, Xue N, Cao J, Tian J, Zhang B, et al. Genetic analysis of arylsulfatase A (ARSA) in Chinese patients with Parkinson’s disease. Neurosci Lett. 2020;734:135094. doi: 10.1016/j.neulet.2020.135094. - DOI - PubMed

Substances